HRS4R
Vull donar

YOLANDA GONZALEZ MONTES

Firma
YOLANDA GONZALEZ-MONTES
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Projectes

Codi oficial: 6822ZB3KJ Data inici: 01/01/2023 Data fi: 31/12/2024 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 0 €

Publicacions

Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

BLOOD CANCER JOURNAL, 2022, 12, 9-9 dx.doi.org/10.1038/s41408-021-00593-2

Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 241-249 dx.doi.org/10.1016/j.clml.2021.10.001
0

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 635-642 dx.doi.org/10.1016/j.clml.2022.04.014
0

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 844-852 dx.doi.org/10.1016/j.clml.2022.04.024

Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ, Bellón JM, García-Sanz R, de la Rubia J, de la Guía AL, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil V, de Arriba F, Pérez-Ávila CC, Gonzalez Y, Hernández MT, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, García A, García-Mateo A, Soler JA, Martín J, Arguiñano JM, Mateos MV, Bladé J, San-Miguel JF, Lahuerta JJ, Martínez-López J, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

BLOOD CANCER JOURNAL, 2022, 12, 68-68 dx.doi.org/10.1038/s41408-022-00652-2

Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R, Sánchez MJ

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 1429-1439 dx.doi.org/10.1007/s12094-020-02541-1

Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

ANNALS OF HEMATOLOGY, 2021, 100, 1769-1778 dx.doi.org/10.1007/s00277-021-04529-5

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Blood, 2019, 134, 1337-1345 dx.doi.org/10.1182/blood.2019000241

Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM, Oriol A

Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19, 585 dx.doi.org/10.1016/j.clml.2019.05.020

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (vol 32, pg 2427, 2018)

Leukemia, 2019, 33, 1056-1056 dx.doi.org/10.1038/s41375-019-0408-x

Formulari de contacte

Coneix l’IDIBGI!

menu